Perspectives - Minireview

Epithelial-mesenchymal Transition and Cell Invasion

Hwajin Son and Aree Moon

College of Pharmacy, Duksung Women's University, Seoul 132-714, Korea

Epithelial-mesenchymal transition (EMT) is a complex process in which epithelial cells acquire the characteristics of invasive mesenchymal cells. EMT has been implicated in cancer progression and metastasis as well as the formation of many tissues and organs during development. Epithelial cells undergoing EMT lose cell-cell adhesion structures and polarity, and rearrange their cytoskeletons. Several oncogenic pathways such as transforming growth factor (TGF)-β, Wnt, and Notch signaling pathways, have been shown to induce EMT. These pathways have activated transcription factors including Snail, Slug, and the ZEB family which work as transcriptional repressors of E-cadherin, thereby making epithelial cells motile and resistant to apoptosis. Mounting evidence shows that EMT is associated with cell invasion and tumor progression. In this review, we summarize the characteristic features of EMT, pathways leading to EMT, and the role of EMT in cell invasion. Three topics are addressed in this review: (1) Definition of EMT, (2) Signaling pathways leading to EMT, (3) Role of EMT in cell invasion. Understanding the role of EMT in cell invasion will provide valuable information for establishing strategies to develop anti-metastatic therapeutics which modulate malignant cellular processes mediated by EMT.

Key words: EMT, cell invasion, TGF-β, Wnt, Notch

INTRODUCTION

Epithelial-mesenchymal transition (EMT) is a central process required for normal embryonic development. Recent evidence suggests roles of EMT for pathological conditions such as cancer progression, fibrosis, and chronic inflammation (Thiery, 2002, 2003; Grunert *et al.*, 2003; Kalluri and Neilson, 2003; Balkwill, 2004). Multi-step processes and various oncogenic signaling pathways are involved in EMT (Derynck and Zhang, 2003; Larue and Bellacosa, 2005; Yee *et al.*, 2010). Conditions where epithelial cells are transformed to a mesenchymal phenotype usually have poor clinical outcomes. The acquisition of EMT features correlates with carcinogenesis, invasion, metastasis, poor survival and an increased risk of cancer recurrence among patients with various solid tumor types, including breast (Trimboli *et al.*, 2008), bladder (Adam *et al.*, 2009), gastric (Kim *et al.*, 2009), and colon cancer (Brabletz *et al.*, 2005).

Correspondence to: Aree Moon, College of Pharmacy, Duksung Women's University, Seoul 132-714, Korea
Email: armoon@duksung.ac.kr

These findings suggest that EMT is required for cell invasion involved in cancer progression.

The present review highlights the current understanding of the role of EMT in cell invasion. The following topics are addressed in this review. **(1) Definition of EMT** - EMT consists of multiple steps in which epithelial cells lose epithelial-specific features and acquire fibroblastoid and mesenchymal features. **(2) Pathways leading to EMT** - Diverse signaling pathways are responsible for regulation of EMT. Mainly, TGF-β, Wnt, and Notch signaling pathways lead to EMT. **(3) Role of EMT in cell invasion** - Tumor cell invasion is necessary for the malignant progression of cancer and EMT is considered as a crucial event in developing invasive potential (Comijn *et al.*, 2001; Christiansen and Rajasekaran, 2006; Lewis-Tuffin *et al.*, 2010; Vuoriluoto *et al.*, 2010). Recent studies on the correlation between EMT and tumor cell invasion are discussed in this review.

Definition of EMT. EMT-associated changes of cell phenotype in embryonic and adult epithelia were first proposed by Trelstad's group and Hay's group (Trelstad *et al.*, 1967; Hay, 1968). In the 1980s, the mesenchymal transformation of early epithelial cells during development was confirmed in chick embryonic lens epithelium (Greenburg and Hey, 1982, 1986). The process of EMT is composed of multiple steps (Voulgari and Pintzas, 2009; Zavadil and

Bottinger, 2005). During EMT, epithelial cells undergo dramatic changes. Epithelial cells lose epithelial cell-specific phenotypes and develop features of mesenchymal cells. Tight- and adherens-junction proteins such as E-cadherin and α-catenin are downregulated and mesenchymal cell-specific marker proteins including N-cadherin, vimentin, and fibronectin are upregulated (Grunert et al., 2003; Christofori, 2006). Subsequently, epithelial cells lose cell-cell adhesion structures and polarity and then obtain cell motility and invasiveness. Finally, epithelial cells undergoing EMT digest and migrate through the extracellular matrix (ECM) and acquire motile and invasive characteristics (Cordon-Cardo and Prives, 1999; Thiery, 2002; Hay, 2005).

Epithelial cells function as an important barrier (Peinado et al., 2007). E-cadherin is a hallmark of epithelial cells, and is encoded by the CDH1 gene (Ghoul, 2009; Humar et al., 2009). This protein is localized at the basolateral membrane in adherens-junctions (Perez-Moreno, 2003), leading to the cell-cell adhesion (Peinado et al., 2007; Roger, 2010). Transcription factors involved in EMT such as Snail, Slug, TWIST, and the ZEB family mainly repress expression of E-cadherin during EMT (Batlle et al., 2000; Cano et al., 2000; Takkunen et al., 2006; Yee et al., 2010).

EMT is associated with intracellular events including embryonic development, wound healing, organ development, and cancer progression (Thiery, 2002, 2003; Grunert et al., 2003; Peinado et al., 2007). Many processes which occur in embryonic development and tissue repair in adult organisms might cause epithelial cells to lose their polarized phenotype. Redistribution of tight-, adherens-junction proteins and migration/scattering of cells occurs when epithelial cells lose of their polarity during many developmental processes. These phenomena are observed in several normal processes including tubulogenesis and branching in the mammary gland, or mesoderm formation; gastrulation, kidney and palate development (reviewed in Grunert et al., 2003).

EMT is controlled by several transcriptional repressors including Snail, Slug, TWIST, and the ZEB family that recruit histone deacetylases to E-box elements that are located in the E-cadherine promoter and a variety of other genes (Peinado et al., 2007). In general, EMT is very complex and strictly controlled in temporal and spatial fashions to ensure proper homing and reversion of cells to non-invasive phenotypes after migration to a destined location and to prevent abnormal development (Hay, 1995; Oft et al., 1998; Brabletz et al., 2001). Cancer cells undergoing EMT lose proper target recognition and activate self-sufficient autocrine loops of growth signals to avoid apoptosis (reviewed in Gotzmann et al., 2004).

Signaling pathways leading to EMT. The key signaling pathways which induce EMT include the TGF-β, Wnt, and Notch signaling pathways. Many of the EMT-inducing pathways control transcription factors of the Snail family (Snail, SLUG) and the ZEB family (ZEB1/2) as well as TWIST which repress expression of E-cadherin (Batlle et al., 2000; Cano et al., 2000; Takkunen et al., 2006; Yee et al., 2010). Here, we summarize the signaling pathways that contribute to the regulation of EMT.

TGF-β signaling pathway: TGF-β is a known multifunctional cytokine, which triggers diverse cellular processes including growth arrest, tissue fibrosis, and EMT (Piek et al., 1999; Moustakas and Heldin, 2007; Schilling et al., 2008). To activate TGF-β signaling pathways, TGF-β binds to TGF-β type II (TβRII) and type I (TβRI) serine/threonine kinase receptors, respectively. TβRII binding to TGF-β transphosphorylates TβRI and the activated TβRI in turn activates R-Smads (Smad2 and Smad3) via phosphorylation at their C-terminal serine residues. As a result, activated R-Smads form a heterocomplex with Smad4 and translocate into the nucleus to regulate gene expression (Akiyoshi et al., 1999; Heldin et al., 1997; Nishihara et al., 1998; Massague and Chen, 2000; Feng and Derynck, 2005). These pathways are termed Smad-dependent pathways. In addition to the Smad signaling pathways, TGF-β also elicits diverse types of non-Smad signaling pathways. Among them, activation of Ras, mitogen-activated protein kinases (MAPKs) such as ERK and p38 MAPK, Rho GTPases, and PI3K/Akt signaling has been linked to TGF-β-induced EMT (Bakin et al., 2000, 2002; Xie et al., 2004; Tavares et al., 2006). These pathways regulate distinct processes including cytoskeleton organization, cell survival, migration, and invasion. Recent studies have shown a crucial role for TGF-β signaling pathways that induce EMT through the Smad-dependent and Smad-independent pathways (Derynck and Zhang, 2003; Davies et al., 2005; Moustakas and Heldin, 2005; Valcourt et al., 2005).

[Smad pathway] Many studies have investigated the roles of the Smad-dependent pathway in TGF-β-induced EMT. When expression of Smad2 or Smad3 was downregulated by a dominant negative mutant, induction of EMT in response to the TGF-β-mediated Smad pathway was blocked in NMuMG cell system (Valcourt et al., 2005). Smad3 is a more important factor than Smad2 in the induction of EMT. Smad3-deficient renal tubular epithelial cells and Smad3[−/−] lens epithelial cells fail to undergo TGF-β-induced EMT (Sato et al., 2003; Saika et al., 2004). In contrast, effects of Smad2 on induction of EMT are controversial. In some cases, Smad2 has negative effects on EMT and cancer progression, e.g., Smad2 deficiency promotes skin tumor formation and EMT in human skin cancer patients and Smad2-lacking keratinocytes (Hoot et al., 2008), and Smad2[−/−] hepatocytes develop mesenchymal characteristics and migratory capability (Ju et al., 2006).

[Non-Smad pathways] Numerous studies have demonstrated that TGF-β also induces EMT via non-Smad pathways, including the Ras-Raf-MEK-ERK, p38 MAPK, and PI3K/Akt signaling pathways.

< Ras-Raf-MEK-ERK pathway>

When TβRI receptor is activated by TGF-β, it phosphorylates Shc, which offers a docking site for the recruitment of Grb2/Sos complex. Phosphorylated Shc forms a complex with Grb2/Sos. Shc/Grb2/Sos complex initiates activation of the Ras signaling cascade (Lee *et al*., 2007). Many observations support a collaboration of TGF-β with the Ras-Raf-MEK1/2-ERK1/2 pathway. Hyper-activated Ras-ERK1/2 pathway due to expression of mutant Ras enhances TGF-β-induced EMT through the loss of epithelial cell-specific features such as the downregulation of E-cadherin expression (Lehmann *et al*., 2000; Grande *et al*., 2002; Uttamsingh *et al*., 2008). Consistent with this observation, MEK1/2, an upstream kinase of ERK1/2, induces activation of ERK1/2 and enhances TGF-β-mediated transcription processes (Grande *et al*., 2002; Uttamsingh *et al*., 2008). This cooperation was confirmed by using an inhibitor to block the kinase function of MEK1/2. Activations of ERK1/2 and TGF-β-induced EMT were blocked using a chemical inhibitor of MEK1/2 (Xie *et al*., 2004).

< p38 MAPK pathway>

TGF-β also triggers phosphorylation of p38 MAPK as well as MKK3/6 and TAK1, which is an activator of MKK3/6 (Santibañez, 2006). Several studies have demonstrated that an inhibitor of p38 MAPK blocks TGF-β-induced EMT in mammary epithelial cells (Bakin *et al*., 2002; Yu *et al*., 2002). The Ras-Rac signaling pathway induces several transcription factors such as Elk-1 and ATF2 through the MKK3/6-p38 MAPK pathways. Eventually, this signaling pathway upregulates expression of Snail-activator for EMT (reviewed in Nawshad *et al*., 2005). In addition to the Ras-MKK3/6-p38 MAPK pathway, TAK1 activates the MKK4-JNK pathway in TGF-β-induced EMT. Accordingly, blocking of JNK activation using a chemical inhibitor prevents expression of proteins associated with TGF-β-induced EMT such as fibronectin and vimentin (Santibañez, 2006).

< PI3K/Akt signaling pathway>

TGF-β induces the PI3K/Akt signaling pathway during EMT in many cell systems (Bakin *et al*., 2000; Lien *et al*., 2006; Lin *et al*., 2007). Consistent with this observation, TβRII and TβRI receptors interact with PI3K, and thus TGF-β stimulates PI3K activity (Yi *et al*., 2005). The PI3K/Akt pathway has been linked to diverse cellular events including cell growth, survival, proliferation, and motility. A PI3K/Akt downstream effector, mTOR, activates S6 kinase 1 during EMT (Lamouille and Derynck, 2007; Sarbassov *et al*., 2005). In turn, S6 kinase 1 regulates the translational machinery, thereby increasing protein synthesis and cell size. S6 kinase 1 is required for the Snail expression (Pon *et al*., 2008). Additionally, several studies have demonstrated that the PI3K/Akt pathway is associated with TGF-β-induced Smad2 phosphorylation, but not with Smad3 phosphorylation (Lamouille and Derynck, 2007; Bakin *et al*., 2000). However, the roles of the PI3K/Akt pathway in

EMT are not fully understood at present.

Wnt signaling pathway: The Wnt pathway has been implicated in EMT during embryonic development and cancer progression as summarized in several recent reviews (Huber *et al*., 2005; Larue and Bellacosa, 2005; Xu *et al*., 2009). In the absence of a Wnt signal, β-catenin is phosphorylated by GSK3 and then undergoes ubiquitin-dependent degradation. This system helps to maintain cytoplasmic β-catenin at a low level. When the Wnt signaling pathway is activated, cytoplasmic β-catenin is accumulated in the nucleus, where it associates with a transcription factor (TCF/LEF) and promotes the expression of target genes involved in EMT. β-catenin/TCF targets Slug (Conacci-Sorrell *et al*., 2003) and stabilizes Snail through blocking of its phosphorylation and degradation (Yook *et al*., 2005).

Mounting studies have documented that the Wnt signaling pathway cooperates with the TGF-β and PI3K/Akt signaling pathways in the context of EMT. For example, Smad2 and Smad4 form a complex with LEF, resulting in repression of E-cadherin gene expression in palate medial-edge epithelial cells. In addition, Smad4 and LEF induce mesenchymal features such as upregulation of fibronectin and vimentin, and the acquisition of migratory capacity (Nawshad *et al*., 2007). At the same time, the PI3K/Akt signaling pathway stabilizes β-catenin through blocking activation of GSK3 (Zhou *et al*., 2004).

Notch signaling pathway: Notch is critical for regulation of cell-cell communication during embryonic development and cancer progression. However, the function of the Notch signaling pathway in EMT is not currently understood. The Notch signaling pathway is activated *via* ligand-receptor interactions between neighboring cells. In turn, Notch is cleaved by proteases, and then the intracellular cleaved form, Notch intracellular domain (NIC), releases from its membrane anchoring. Upon activation, the NIC translocates into the nucleus, where it binds to the transcription factor CSL which upregulates Hey1, a well-known target gene of Notch signaling, and Snail (Timmerman *et al*., 2004; Zavadil *et al*., 2004). The Notch signaling pathway crosstalks with the TGF-β pathway. Hey1 is required for TGF-β-induced EMT and migration in epithelial cells (Zavadil *et al*., 2004).

Role of EMT in cell invasion. Metastasis, the major cause of death in cancer patients, is the spread of a tumor from its primary site to other location in the body. Cell invasion has been recognized as a key step in metastasis and results from various factors and oncogenic signaling pathways which overlap with EMT-inducing pathways (Boyer *et al*., 2000). Cancer cells undergoing EMT generally lose proper target recognition and activate self-sufficient autocrine loops of growth signals - mechanisms to avoid apoptosis (reviewed in Gotzmann *et al*., 2004). It has been documented that cell invasion during cancer progression

may be critically dependent on the acquisition of EMT features (Kang and Massague, 2004; Thiery and Morgan, 2004). These findings suggest that EMT is associated with cell invasion involved in cancer malignancy.

The association between EMT and cell invasion has been demonstrated in cancer progression. Matrix metalloproteinases (MMPs), especially, MMP-2 and -9, are deeply involved in invasion and metastasis. Increased enzymatic degradation of extracellular matrix components by MMPs induces cell invasion and tumor spread (Platten *et al*., 2001; Wick *et al*., 2001). Studies suggest that MMPs stimulate EMT and that EMT produces MMPs (reviewed in Radisky and Radisky, 2010). In addition, signaling pathways involved in EMT, such as TGF-β, Wnt, and Notch signaling pathways are associated with cancer progression.

MMPs are an important mediator of various cellular events, including ECM degradation and remodeling, cell proliferation, apoptosis, cell invasion/migration and morphological change (Sternlicht and Werb, 2001). MMPs act in malignant cancer progression through degradation of ECM, stimulation of EMT and the induction of cell invasion (Kim *et al*., 2003; Duong and Erickson, 2004; Illman *et al*., 2006; Song *et al*., 2006). Each of the MMPs has a different substrate, for example, MMP-1, -8, and -13 are collagen-cleaving MMPs, while MMP-2 and -9 are gelatin-cleaving MMPs (reviewed in Snoek-van Beurden and Von den Hoff, 2005). Increased expression of MMPs has been suggested as a marker for tumor aggressiveness in breast, lung, pancreatic, and prostate cancers (Jones *et al*., 2004; Morgia *et al*., 2005; Somiari *et al*., 2006; Liu *et al*., 2007).

Recent studies have shown that MMPs stimulate EMT in various epithelial cell types, including kidney, ovary, lung, prostate, lens and breast epithelial cells (reviewed in Radisky and Radisky, 2010). According to several findings, MMPs are implicated in EMT during cancer progression *via* three mechanisms: (a) increased MMPs in the tumor microenvironment can directly induce EMT in epithelial cells, (b) cancer cells undergoing EMT can produce more MMPs and then facilitate cell invasion, and (c) epithelial cells can undergo EMT through further MMP production. For example, overexpression of MMP-7, 28 induces stable EMT in A549 lung adenocarcinoma cells (McGuire *et al*., 2003; Illman *et al*., 2006), and MMP-3 in MCF-7 human breast cancer cells and SCp2 mouse mammary epithelial cells (Noel *et al*., 2000; Radisky *et al*., 2005). MMP-2 becomes activated in neural cells undergoing EMT (Duong and Erickson, 2004) and MMP inhibitors block mesenchyme formation (Song *et al*., 2000).

Recent studies suggest that microRNA (miRNA, miR) is associated with EMT (reviewed in Zavadil *et al*., 2007; McConkey *et al*., 2009). miRNAs have been known as non-coding RNAs which act as post-transcriptional repressors of gene functions through translation inhibition and degradation of target mRNAs. miRNAs are often deregulated in diseases such as cancer. Several findings have shown that the miR-200 family plays a critical role in EMT through regulation of ZEB family levels. Interestingly, the ZEB family can also repress the miR-200 family. When the miR-200 family is downregulated by the ZEB family, E-cadherin expression is suppressed and cell motility and invasiveness are increased. These feedback loops are in place to fine-tune EMT-related signaling. Recently, Zavadil *et al*. (2007) revealed a novel EMT-specific microRNA, miR-21, which is a candidate oncogenic microRNA associated with carcinogenesis.

Further functional studies on the interactions of MMP, miRNA and EMT may provide promising therapeutic approaches for the treatment of cancer. The above mentioned pathways leading to EMT, and crosstalk among these pathways can promote cell invasion and the progression of malignant cancer (Reiss and Barcellos-Hoff, 1997; Taki *et al*., 2003; Brabletz *et al*., 2005; Kim *et al*., 2005; Larue and Bellacosa, 2005; Wang *et al*., 2006).

CONCLUSIONS

Cancer cell invasion is a major factor and the first step in cancer metastasis which is the feature of malignant tumors resulting in dissemination of primary tumor cells to distant organs. To develop effective treatments for invasion and substantially improve patient prognosis, we need to understand the mechanism of cancer cell invasion and identify potential therapeutic targets related to metastasis.

Mounting evidence shows that EMT has been linked to an invasive phenotype as well as solid tumor progress (reviewed in Micalizzi *et al*., 2010). EMT promotes malignancy in various cancer types including prostate, gastric, bladder, lung and breast cancer. Epithelial cells change their phenotype and acquire features of mesenchymal cells in a cancer microenvironment *via* EMT. Since EMT plays a key role in tumor cell invasion and cancer metastasis, establishing strategies to control EMT-inducing signaling should be a high priority for the development of anti-metastatic therapeutics.

In this review, we summarized a portion of recent findings on EMT-inducing signaling and discussed how EMT facilitates cell invasion and cancer progression. EMT is induced through diverse signaling pathways, including the TGF-β, PI3K/Akt, Wnt, and Notch signaling pathways. These signaling pathways crosstalk with each other and then facilitate EMT and cell invasion.

Although much is known about the functions of EMT in cell invasion, more must be understood to provide detailed information on the molecular mechanisms leading to an invasive phenotype. Understanding the relationship between EMT and cell invasion might provide useful information that can lead to the future development of novel targets for prognosis and/or therapy of cancer progression.

ACKNOWLEDGMENTS

REFERENCES

Adam, L., Zhong, M., Choi, W., Qi, W., Nicoloso, M., Arora, A., Calin, G., Wang, H., Siefker-Radtke, A., McConkey, D., Bar-Eli, M. and Dinney, C. (2009). miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. *Clinical Cancer Research*, **15**, 5060-5072.

Akiyoshi, S., Inoue, H., Hanai, J., Kusanagi, K., Nemoto, N., Miyazono, K. and Kawabata, M. (1999). c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. *J. Biol. Chem.*, **274**, 35269-35277.

Bakin, A.V., Rinehart, C., Tomlinson, A.K. and Arteaga, C.L. (2002). p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. *J.Cell Sci.*, **115**, 3193-3206.

Bakin, A.V., Tomlinsos, A.K., Bhowmick, N.A., Moses, H.L. and Arteaga, C.L. (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor-â-mediated epithelial to mesenchymal transition and cell migration. *J. Biol. Chem.*, **275**, 36803-36810.

Balkwill, F. (2004). Cancer and the chemokine network. *Nat. Rev. Cancer*, **4**, 540-550.

Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J. and García De Herreros, A. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat. Cell. Biol.*, **2**, 84-89.

Boyer, B., Valles, A.M. and Edme, N. (2000). Induction and regulation of epithelial-mesenchymal transitions. *Biochem. Pharmacol.*, **60**, 1091-1099.

Brabletz, T., Hlubek, F., Spaderna, S., Schmalhofer, O., Hiendlmeyer, E., Jung, A. and Kirchner T. (2005). Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. *Cells Tissues Organs*, **179**, 56-65.

Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R. and Kirchner, T. (2001). Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. *Proc. Natl. Acad. Sci.*, **98**, 10356-10361.

Cano, A., Pérez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G., Portillo, F. and Nieto, M.A. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat. Cell Biol.*, **2**, 76-83.

Christiansen, J.J. and Rajasekaran, A.K. (2006). Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. *Cancer Res.*, **66**, 8319-8326.

Christofori, G. (2006). New signals from the invasive front. *Nature*, **441**, 444-450.

Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D. and van Roy, F. (2001). The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. *Mol. Cell*, **7**, 1267-1278.

Conacci-Sorrell, M., Simcha, I., Ben-Yedidia, T., Blechman, J., Savagner, P. and Ben-Ze'ev, A. (2003). Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. *J. Cell Biol.*, **163**, 847-857.

Cordon-Cardo, C. and Prives, C. (1999). At the crossroads of inflammation and tumorigenesis. *J. Exp. Med.*, **190**, 1367-1370.

Davies, M., Robinson, M., Smith, E., Huntley, S., Prime, S. and Paterson, I. (2005). Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. *J. Cell Biochem.*, **95**, 918-931.

Derynck, R. and Zhang, Y.E. (2003). Smad-dependent and Smad-independent pathways in TGF-b family signalling. *Nature*, **425**, 577-584.

Duong, T.D. and Erickson, C.A. (2004). MMP-2 plays an essential role in producing epithelial-mesenchymal transformations in the avian embryo. *Dev. Dyn.*, **229**, 42-53.

Feng, X.H. and Derynck, R. (2005). Specificity and versatility in TGF-beta signaling through Smads. *Annu. Rev. Cell Dev. Biol.*, **21**, 659-693.

Ghoul, A., Serova, M., Astorgues-Xerri, L., Bieche, I., Bousquet, G., Varna, M., Vidaud, M., Phillips, E., Weill, S., Benhadji, K.A., Lokiec, F., Cvitkovic, E., Faivre, S. and Raymond, E. (2009). Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. *Cancer Res.*, **69**, 4260-4269.

Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H. and Mikulits, W. (2004). Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. *Mutat. Res.*, **566**, 9-20.

Grande, M., Franzen, A., Karlsson, J.O., Ericson, L.E., Heldin, N.E. and Nilsson, M. (2002). Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. *J. Cell. Sci.*, **115**, 4227-4236.

Greenburg, G. and Hay, E.D. (1982). Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. *J. Cell. Biol.*, **95**, 333-339.

Greenburg, G. and Hay, E.D. (1986). Cytodifferentiation and tissue phenotype change during transformation of embryonic lens epithelium to mesenchyme-like cells in vitro. *Dev. Biol.*, **115**, 363-379.

Grunert, S., Jechlinger, M. and Beug, H. (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. *Nat. Rev. Mol. Cell. Biol.*, **4**, 657-665.

Hay, E.D. (1968). Organization and fine structure of epithelium and mesenchyme in the developing chick embryo. In Epithelial-Mesenchymal Interactions; 18th Hahnemann Symposium, (eds. R. Fleischmajer, & R. E. Billingham), Williams & Wilkins, Baltimore.

Hay, E.D. (1995). An overview of epithelio-mesenchymal transformation. *Acta. Anat.*, **154**, 8-20.

Hay, E.D. (2005). The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. *Dev.*

Dyn., **233**, 706-720.

Heldin, C.H., Miyazono, K. and ten Dijke, P. (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. *Nature*, **390**, 465-471.

Hoot, K.E., Lighthall, J., Han, G., Lu, S.L., Li, A., Ju, W., Kulesz-Martin, M., Bottinger, E. and Wang, X.J. (2008). Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. *J. Clin. Invest.*, **118**, 2722-2732.

Huber, M.A., Kraut, N. and Beug, H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr. Opin. Cell. Biol.*, **17**, 548-558.

Humar, B., Blair, V., Charlton, A., More, H., Martin, I. and Guilford, P. (2009). E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. *Cancer Res.*, **69**, 2050-2056.

Illman, S.A., Lehti, K., Keski-Oja, J. and Lohi, J.(2006). Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. *J. Cell Sci.*, **119**, 3856-3865.

Jones, L.E., Humphreys, M.J., Campbell, F., Neoptolemos, J.P. and Boyd, M.T. (2004). Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. *Clin. Cancer Res.*, **10**, 2832-2845.

Ju, W., Ogawa, A., Heyer, J., Nierhof, D., Yu, L., Kucherlapati, R., Shafritz, D.A. and Böttinger, E.P. (2006). Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. *Mol. Cell. Biol.*, **26**, 654-667.

Kalluri, R. and Neilson, E.G. (2003). Epithelial-mesenchymal transition and its implications for fibrosis. *J. Clin. Invest.*, **112**, 1776-1784.

Kang, Y. and Massague, J. (2004). Epithelial-mesenchymal transitions: twist in development and metastasis. *Cell*, **118**, 277-279.

Kim, E.S., Kim, M.S. and Moon, A. (2005). Transforming growth factor (TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. *Cytokine*, **29**, 84-91.

Kim, M.S., Lee, E.J., Kim, H.R. and Moon, A. (2003). p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. *Cancer Res.*, **63**, 5454-5461.

Kim, M.A., Lee, H.S., Lee, H.E., Kim, J.H., Yang, H.K. and Kim, W.H. (2009). Prognostic importance of epithelial-mesenchymal-related protein expression in gastric carcinoma. *Histopathology*, **54**, 442-451.

Lamouille, S. and Derynck, R. (2007). Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. *J. Cell Biol.*, **178**, 437-451.

Larue, L. and Bellacosa, A. (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. *Oncogene*, **24**, 7443-7454.

Lee, M.K., Pardoux, C., Hall, M.C., Lee, P.S., Warburton, D., Qing, J., Smith, S.M. and Derynck, R. (2007). TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. *EMBO J.*, **26**, 3957-3967.

Lehmann, K., Janda, E., Pierreux, C.E., Rytömaa, M., Schulze, A., McMahon, M., Hill, C.S., Beug, H. and Downward, J. (2000).

Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. *Genes Dev.*, **14**, 2610-2622.

Lewis-Tuffin, L.J., Rodriguez, F., Giannini, C., Scheithauer, B., Necela, B.M., Sarkaria, J.N. and Anastasiadis, P.Z. (2010). Misregulated e-cadherin expression associated with an aggressive brain tumor phenotype. *PLoS One*, **5**, e13665.

Lien, S.C., Usami, S., Chien, S. and Chiu, J.J. (2006). Phosphatidylinositol 3-kinase/Akt pathway is involved in transforming growth factor-beta1-induced phenotypic modulation of 10T1/2 cells to smooth muscle cells. *Cell Signal*, **18**, 1270-1278.

Lin, C.C., Chiang, L.L., Lin, C.H., Shih, C.H., Liao, Y.T., Hsu, M.J. and Chen, B.C. (2007). Transforming growth factor-beta1 stimulates heme oxygenase-1 expression via the PI3K/Akt and NF-kappaB pathways in human lung epithelial cells. *Eur. J. Pharmacol.*, **560**, 101-109.

Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., Ueno, M., Kadota, K., Urushihara, M. and Huang, C.L. (2007). Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. *Lung Cancer*, **58**, 384-391.

Massague, J. and Chen, Y.G. (2000). Controlling TGF-beta signaling. *Genes Dev.*, **14**, 627-644.

McConkey, D.J., Choi, W., Marquis, L., Martin, F., Williams, M.B., Shah, J., Svatek, R., Das, A., Adam, L., Kamat, A., Siefker-Radtke, A. and Dinney, C. (2009). Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. *Cancer Metastasis Rev.*, **28**, 335-344.

McGuire, J.K., Li, Q. and Parks, W.C. (2003). Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. *Am. J. Pathol.*, **162**, 1831-1843.

Micalizzi, D.S., Farabaugh, S.M. and Ford, H.L. (2010). Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. *J. Mammary Gland Biol. Neoplasia*, **15**, 117-134.

Morgia, G., Falsaperla, M., Malaponte, G., Madonia, M., Indelicato, M., Travali, S. and Mazzarino, M.C. (2005). Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. *Urol Res.*, **33**, 44-50.

Moustakas, A. and Heldin, C.H. (2005). Non-Smad TGF-beta signals. *J. Cell Sci.*, **118**, 3573-3584.

Moustakas, A. and Heldin, C.H. (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and caner progression. *Cancer Sci.*, **98**, 1512-1520.

Nawshad, A., Lagamba, D., Polad, A. and Hay, E.D. (2005). Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. *Cells Tissues Organs*, **179**, 11-23.

Nawshad, A., Medici, D., Liu, C.C. and Hay, E.D. (2007). TGFbeta3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. *J. Cell. Sci.*, **120**, 1646-1653.

Nishihara, A., Hanai, J.I., Okamoto, N., Yanagisawa, J., Kato, S., Miyazono, K. and Kawabata, M. (1998). Role of p300, a transcriptional coactivator, in signalling of TGF-beta. *Genes Cells*, **3**, 613-623.

Noel, A., Boulay, A., Kebers, F., Kannan, R., Hajitou, A., Calberg-Bacq, C.M., Basset, P., Rio, M.C. and Foidart, J.M. (2000). Demonstration in vivo that stromelysin-3 functions through its

proteolytic activity. *Oncogene*, **19**, 1605-1612.

Oft, M., Heider, K.H. and Beug, H. (1998). TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. *Curr. Biol.*, **8**, 1243-1252.

Peinado, H., Olmeda, D. and Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nature Reviews Cancer*, **7**, 415-428.

Perez-Moreno, M., Jamora, C. and Fuchs, E. (2003). Sticky business: orchestrating cellular signals at adherens junctions. *Cell*, **112**, 535-548.

Piek, E., Moustakas, A., Kurisaki, A., Heldin, C.H. and Ten Dijke, P. (1999). TGF-β type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. *J. Cell Sci.*, **112**, 4557-4568.

Platten, M., Wick, W. and Weller, M. (2001). Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. *Microsc. Res. Tech.*, **52**, 401-410.

Pon, Y.L., Zhou, H.Y., Cheung, A.N., Ngan, H.Y. and Wong, A.S. (2008). p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. *Cancer Res.*, **68**, 6524-6532.

Radisky, E.S. and Radisky, D.C. (2010). Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. *J. Mammary Gland Biol. Neoplasia.*, **15**, 201-212.

Radisky, D.C., Levy, D.D., Littlepage, L.E., Liu, H., Nelson, C.M., Fata, J.E., Leake, D., Godden, E.L., Albertson, D.G., Nieto, M.A., Werb, Z. and Bissell, M.J. (2005). Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. *Nature*, **436**, 123-127.

Reiss, M. and Barcellos-Hoff, M.H. (1997). Transforming growth factor-beta in breast cancer: a working hypothesis. *Breast Cancer Res. Treat.*, **45**, 81-95.

Roger, L., Jullien, L., Gire, V. and Roux, P. (2010). Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. *J. Cell Sci.*, **123**, 1295-1305.

Saika, S., Kono-Saika, S., Ohnishi, Y., Sato, M., Muragaki, Y., Ooshima, A., Flanders, K.C., Yoo, J., Anzano, M., Liu, C.Y., Kao, W.W. and Roberts, A.B. (2004). Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. *Am. J. Pathol.*, **164**, 651-663.

Santibañez, J.F. (2006). JNK mediates TGF-beta1-induced epithelial mesenchymal transdifferentiation of mouse transformed keratinocytes. *FEBS Lett.*, **580**, 5385-5391.

Sarbassove, D.D., Ali, S.M., and Sabatini, D.M. (2005). Growing roles for the mTOR pathway. *Curr. Opin. Cell Biol.*, **17**, 596-603.

Sato, M., Muragaki, Y., Saika, S., Roberts, A.B. and Ooshima, A. (2003). Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. *J. Clin. Invest.*, **112**, 1486-1494.

Schilling, S.H., Hjelemeland, A.B., Rich, J.N. and Wang, X.F. (2008). TGF-β Family (eds. Derynck, R., and Miyazono, K.). Cold Spring Harbor Laboratory Pres, New York, pp. 45-78.

Snoek-van Beurden, P.A. and Von den Hoff, J.W. (2005). Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. *Biotechniques*, **38**, 73-83.

Somiari, S.B., Somiari, R.I., Heckman, C.M., Olsen, C.H., Jordan, R.M., Russell, S.J. and Shriver, C.D. (2006). Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. *Int. J. Cancer*, **119**, 1403-1411.

Song, H., Ki, S.H., Kim, S.G. and Moon, A. (2006). Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. *Cancer Res.*, **66**, 10487-10496.

Song, W., Jackson, K. and McGuire, P.G. (2000). Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. *Dev. Biol.*, **227**, 606-617.

Taki, M., Kamata, N., Yokoyama, K., Fujimoto, R., Tsutsumi, S. and Nagayama, M. (2003). Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. *Cancer Sci.*, **94**, 593-597.

Takkunen, M., Grenman, R., Hukkanen, M., Korhonen, M., García de Herreros, A. and Virtanen, I. (2006). Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. *J. Histochem. Cytochem.*, **54**, 1263-1275.

Tavares, A.L., Mercado-Pimentel, M.E., Runyan, R.B. and Kitten, G.T. (2006). TGF-β-mediated RhoA expression is necessary for epithelial-mesenchymal transition in the embryonic chick heart. *Dev. Dyn.*, **235**, 1589-1598.

Thiery, J.P. (2002). Epithelial-mesenchymal transitions in tumour progression. *Nat. Rev. Cancer*, **2**, 442-454.

Thiery, J.P. (2003). Epithelial-mesenchymal transitions in development and pathologies. *Curr. Opin. Cell. Biol.*, **15**, 740-746.

Thiery, J.P. and Morgan, M. (2004). Breast cancer progression with a Twist. *Nat. Med.*, **10**, 777-778.

Timmerman, L.A., Grego-Bessa, J., Raya, A., Bertrán, E., Pérez-Pomares, J.M., Díez, J., Aranda, S., Palomo, S., McCormick, F., Izpisúa-Belmonte, J.C. and de la Pompa, J.L. (2004). Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. *Genes Dev.*, **18**, 99-115.

Trelstad, R.L., Hay, E.D. and Revel, J.D. (1967). Cell contact during early morphogenesis in the chick embryo. *Dev. Biol.*, **16**, 78-106.

Trimboli, A.J., Fukino, K., de Bruin, A., Wei, G., Shen, L., Tanner, S.M., Creasap, N., Rosol, T.J., Robinson, M.L., Eng, C., Ostrowski, M.C. and Leone, G. (2008). Direct evidence for epithelial-mesenchymal transitions in breast cancer. *Cancer Res.*, **68**, 937-945.

Uttamsingh, S., Bao, X., Nguyen, K.T., Bhanot, M., Gong, J., Chan, J.L., Liu, F., Chu, T.T. and Wang, L.H. (2008). Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. *Oncogene*, **27**, 2626-2634.

Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C.H. and Moustakas, A. (2005). TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. *Mol. Biol. Cell*, **16**, 1987-2002.

Voulgari, A. and Pintzas, A. (2009). Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. *Biochim. Biophys. Acta.*, **1796**, 75-90.

Vuoriluoto, K., Haugen, H., Kiviluoto, S., Mpindi, J.P., Nevo, J.,

Gjerdrum, C., Tiron, C., Lorens, J.B. and Ivaska, J. (2010). Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. *Oncogene*, Epub ahead of print.

Wang, Z., Banerjee, S., Li, Y., Rahman, K.M., Zhang, Y. and Sarkar, F.H. (2006). Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. *Cancer Res.*, **66**, 2778-2784.

Wick, W., Platten, M. and Weller, M. (2001). Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. *J. Neurooncol.*, **53**, 177-185.

Xie, L., Law, B.K., Chytil, A.M., Brown, K.A., Aakre, M.E. and Moses, H.L. (2004). Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. *Neoplasia*, **6**, 603-610.

Xu, J., Lamouille, S. and Derynck, R. (2009). TGF-beta-induced epithelial to mesenchymal transition. *Cell Res.*, **19**, 156-172.

Yee, D.S., Tang, Y., Li, X., Liu, Z., Guo, Y., Ghaffar, S., McQueen, P., Atreya, D., Xie, J., Simoneau, A.R., Hoang, B.H. and Zi, X. (2010). The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. *Mol. Cancer*, **9**, 162.

Yi, J.Y., Shin, I. and Arteaga, C.L. (2005). Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. *J. Biol. Chem.*, **280**, 10870-10876.

Yook, J.I., Li, X.Y., Ota, I., Fearon, E.R. and Weiss, S.J. (2005). Wnt-dependent regulation of the E-cadherin repressor snail. *J. Biol. Chem.*, **280**, 11740-11748.

Yu, L., Hébert, M.C. and Zhang, Y.E. (2002). TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. *EMBO J.*, **21**, 3749-3759.

Zavadil, J. and Bottinger, E.P. (2005). TGF-beta and epithelial-to-mesenchymal transitions. *Oncogene*, **24**, 5764-5774.

Zavadil, J., Cermak, L., Soto-Nieves, N. and Böttinger, E.P. (2004). Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. *EMBO J.*, **23**, 1155-1165.

Zavadil, J., Narasimhan, M., Blumenberg, M. and Schneider, R.J. (2007). Transforming growth factor-beta and microRNA: mRNA regulatory networks in epithelial plasticity. *Cells Tissues Organs*, **185**, 157-161.

Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gunduz, M. and Hung, M.C. (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. *Nat. Cell Biol.*, **6**, 931-940.